SMARTDIABETES, the consortium led by the start-up SocialDiabetes, a member of CATALONIA.HEALTH, will receive '1.15 million in funding by the end of 2025 from EIT Health.  

The pharmaceutical company Croda Pharma, member of CATALONIA.HEALTH, announces the launch of Super RefinedTM Poloxamer 188, an innovative bioprocessing solution developed to meet the growing demands of biopharmaceutical development.  

Germans Trias i Pujol Research Institute (IGTP), member of CATALONIA.HEALTH, announces the creation of two new spin-offs: Debios Diagnostics and HealthTech Innovations.

The advanced therapeutics company Integra Therapeutics, member of CATALONIA.HEALTH, and the Lithuanian company Caszyme have announced a license agreement for the use of Cas12I, Caszyme’s innovative nucleoases, to develop safer and more efficient gene and cell therapies.

The company INBRAIN Neuroelectronics, a member of CATALONIA.HEALTH, announces the closure of a $50 million Series B financing round. The round has been led by imec.xpand with new investors such as EIC Fund, Fond-ICO Next Tech, CDTI-Innvierte and Avançsa.

Life sciences venture capital company Asabys Partners, member of CATALONIA.HEALTH, announces the investment in the biotech company Agomab Therapeutics in a Series D financing round that reaches $89 million, along with other existing investors, and with Sanofi and Invius, which join as new investors.

The new compound AOP208, initially developed by Leukos Biotech, a spin-off of the Josep Carreras Leukemia Research Institute, both members of CATALONIA.HEALTH, has been tested for the first time in patients in the SERONCO-1 phase 1 clinical trial, to assess their safety in patients with advanced solid tumors that is being carried out at the UITM-CaixaResearch Molecular Cancer Therapy Research Unit of the Vall de Hebron Institute of Oncology (VHIO). 

The general director and co-founder of the company specialized in visual and cognitive improvement WIVI Vision, member of CATALONIA.HEALTH, Eva García, wins the Dona TIC 2024 Award in the category of entrepreneur. 

Specialists from the health and technology sector have debated the opportunities and challenges that artificial intelligence presents for the health sector as a whole: improving process efficiency and innovation in the industrial and healthcare fields.

The leading international group in the production of pharmaceutical active ingredients Moehs, member of CATALONIA.HEALTH, has signed an exclusive agreement with EUROAPI to assume the production of Metamizol, the active ingredient of the drug Nolotil, in its facilities in Spain.  

A worldwide leader in specialized diagnostics Werfen, member of CATALONIA. HEALTH, announces the finalization of a partnership agreement with Seegene Inc. Under the agreement, Seegene and Werfen will set up a NewCo in Spain, Werfen-Seegene, upon the conclusion of mandatory government approvals anticipated by the first half of 2025.

The company dedicated to personalized medicine Inbiomotion, member of CATALONIA.HEALTH, have signed an exclusive agreement to start offering the MAF Test® in Italy.

The biopharmaceutical company Oryzon Genomics, member of CATALONIA.HEALTH, announces that it has received the official record of its recent meeting of End-of-Phase II for vafidemstaten for Personality Limit Disorder (TLP) with the US Food and Drug Administration (FDA). ORYZON will begin the preparation of a complete protocol for the study of Phase III PORTICO-2 that will soon be presented to the FDA for approval.  

The UMBRELLA consortium, led by Vall d'Hebron Research Institute (VHIR), a member of CATALONIA.HEALTH, and the company Siemens Healthineers, is made up of more than 20 public and private partners whose objective is to revolutionize the entire stroke care process in Europe.

The biotechnology company Archivel Farma, a member of CATALONIA.HEALTH, announces the opening of a business line as the Contract Development and Manufacturing Organization (CDMO). The initiative will focus on the manufacture of clinical batches under Good Manufacturing Practices (GMP).

The pharmaceutical company Almirall, member of CATALONIA.HEALTH, launches the new Ebglyss treatment (lebrikizumab) in Spain. This monoclonal antibody is already available for the treatment of adult and teen patients with atopic dermatitis from moderate to severe and who are candidates for systemic therapy.  

The “deeptech” and leading bioinformatics company Sequentia Biotech, member of CATALONIA.HEALTH, obtains a €10 million Series A investment, which is led by Seventure Partners, and co-invested by the EIC Fund. The investment will accelerate Sequentia Biotech’s mission to drive innovation in the field of omics.

INBRAIN Neuroelectronics, member of CATALONIA.HEALTH, has announced the world's first application of a graphene interface in a human patient. This intervention was performed on a patient undergoing resection (removal) of a brain tumor. The company is a spin-off of ICN2 and CSIC. 

The pioneering company in the life sciences venture capital sector Asabys Partner, member of CATALONIA.HEALTH, announced today the successful final close of its second fund, Sabadell Asabys Health Innovation Investments II (SAHII II) with total commitments of €180 million ($200M), exceeding its initial target of €150 million.

About twenty professionals from companies and member entities of CATALONIA.HEALTH met this past September 18th, at the Hub Cambra Digital in Barcelona, for the first appointment on the agenda of activities after the summer. It was the fourth edition of this year of the CEO Council sessions with Josep Maria Argimon as a special guest.